ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Triggering global regulatory submissions this year for the treatment of obesity
The complex four-hour surgery was performed by a multidisciplinary team of doctors
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Subscribe To Our Newsletter & Stay Updated
